Vancouver, British Columbia–(Newsfile Corp. – January 31, 2025) – Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the “Firm” or “Moss”) is happy to announce that’s has closed its beforehand introduced non-brokered personal placement of 2,500,000 frequent shares (every a “Share”) at $0.10 per Share for whole gross proceeds of $250,000 (the “Providing”). Concurrently, with the closing of the Providing, the Firm proclaims closing of its acquisition of 160 Ethereum cryptocurrency (“ETH”) in consideration for the issuance of 7,840,000 frequent shares (the “ETH Acquisition”).
The Providing and ETH Acquisition stays topic to last acceptance from the Canadian Securities Trade. All securities issued in reference to the Providing and ETH Acquisition might be topic to a statutory maintain interval expiring 4 months plus someday from closing.
The Firm intends to use the web proceeds of the Providing and the ETH Acquisition for common working capital functions.
The securities being supplied haven’t been and won’t be registered beneath the U.S. Securities Act and might not be supplied or offered in america, or to, or for the account or profit of, U.S. individuals or individuals in america, absent registration or an relevant exemption from the registration necessities. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any sale of the securities in any State during which such supply, solicitation or sale could be illegal.
Appointment of Hunter Jordan
The Firm is happy to announce that it has appointed Hunter Jordan to its Board of Directors.
Hunter is a VP at a personal actual property agency, specializing in world actual property working firm investments. On this function, he leads strategic initiatives to set up and scale platforms whereas optimizing governance constructions. Hunter started his profession at PwC, incomes his CPA designation, and has labored throughout a number of sectors and areas.
The Firm additionally proclaims that it has granted a complete of 200,000 inventory choices to sure administrators, officers and consultants of the Firm. Every possibility is exercisable to buy one frequent share of the Firm at an train worth of $0.20 for a interval of 5 years.
About Moss Genomics Inc.
Moss is a biotechnology firm using Synthetic Intelligence, Genomic, Microbiome, and a various array of well being knowledge to develop distinctive and modern well being options. By integrating blockchain and superior treasury methods, Moss seeks to leverage fashionable developments in know-how within the life sciences trade.
For additional info regarding Moss and its enterprise please view the Firm’s web site at mossgenomics.com and its SEDAR+ profile at www.sedarplus.ca or contact us at:
CONTACT INFORMATIONMoss Genomics Inc.
Jack Liu, Chief Govt Officer and Director
E-mail: invest@mossgen.coPhone: 604-710-0124
The CSE has neither accredited nor disapproved the contents of this information launch. Neither the CSE nor its Market Regulator (as that time period is outlined within the insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch.
Ahead Trying Data
This launch contains sure statements and info which will represent forward-looking info throughout the that means of relevant Canadian securities legal guidelines. Ahead-looking statements relate to future occasions or future efficiency and mirror the expectations or beliefs of administration of the Firm relating to future occasions. Usually, forward-looking statements and info will be recognized by the use of forward-looking terminology similar to “intends” or “anticipates”, or variations of such phrases and phrases or statements that sure actions, occasions or outcomes “could”, “may”, “ought to”, “would” or “happen”. This info and these statements, referred to herein as “ahead‐wanting statements”, should not historic information, are made as of the date of this information launch and embody with out limitation, statements relating to discussions of future plans, estimates and forecasts and statements as to administration’s expectations and intentions with respect to, amongst different issues: regulatory approval of the Providing, the ETH Acquisition and the supposed use of proceeds raised beneath the Providing.
These ahead‐wanting statements contain quite a few dangers and uncertainties and precise outcomes would possibly differ materially from outcomes recommended in any forward-looking statements. These dangers and uncertainties embody, amongst different issues: delays in acquiring or failure to acquire the required regulatory approvals for the Providing and the ETH Acquisition; market uncertainty; and adjustments within the Firm’s enterprise plans impacting the supposed use of proceeds raised beneath the Providing.
In making the ahead wanting statements on this information launch, the Firm has utilized a number of materials assumptions, together with with out limitation, that: the Firm will acquire the required regulatory approvals for the Providing and the ETH Acquisition; and the Firm will use the proceeds of the Providing as presently anticipated.
Though administration of the Firm has tried to establish necessary components that might trigger precise outcomes to differ materially from these contained in forward-looking statements or forward-looking info, there could also be different components that trigger outcomes not to be as anticipated, estimated or supposed. There will be no assurance that such statements will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in such statements. Accordingly, readers shouldn’t place undue reliance on forward-looking statements and forward-looking info. Readers are cautioned that reliance on such info might not be applicable for different functions. The Firm doesn’t undertake to replace any forward-looking assertion, forward-looking info or monetary out-look which can be included by reference herein, besides in accordance with relevant securities legal guidelines.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239281
